Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 S-1/oxaliplatin with or without ramucirumab as first-line therapy in metastatic gastric or GEJ adenocarcinoma
jRCT2080222999Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ramucirumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Eli Lilly and Company. Started Oct 2015; status: completed.
02
Drugs
ramucirumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on jRCT2080222999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222999.